Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TraSki: Tralokinumab effects on skin barrier in atopic dermatitis
NCT04556461Phase 2Completed
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tralokinumab in atopic dermatitis (AD). Primary endpoint: Skin barrier function at 16 weeks. Started Sep 2020; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04556461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556461.